136 related articles for article (PubMed ID: 8543319)
41. Growth effects of raloxifene, estradiol, medroxy-progesterone acetate, and progesterone on human endometrial adenocarcinoma cells.
Boostanfar R; Amezcua CA; Tourgeman DE; Roy S; Felix JC; Stanczyk FZ
Fertil Steril; 2003 Jan; 79(1):223-5. PubMed ID: 12524096
[No Abstract] [Full Text] [Related]
42. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.
Duska LR; Filiaci VL; Walker JL; Holman LL; Hill EK; Moore RG; Ring KL; Pearl ML; Muller CY; Kushnir CL; Lankes HA; Samuelson MI; Carrick KS; Rajan A; Rodgers WH; Kohn EC; Piekarz R; Leslie KK
Clin Cancer Res; 2021 May; 27(10):2734-2741. PubMed ID: 33766814
[TBL] [Abstract][Full Text] [Related]
43. Fertility-sparing therapy for young women with endometrial cancer.
Frumovitz M; Gershenson DM
Expert Rev Anticancer Ther; 2006 Jan; 6(1):27-32. PubMed ID: 16375641
[TBL] [Abstract][Full Text] [Related]
44. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
45. Long-term outcomes of fertility-sparing treatment of atypical polypoid adenomyoma with medroxyprogesterone acetate.
Nomura H; Sugiyama Y; Tanigawa T; Matoda M; Kanao H; Kondo E; Takeshima N
Arch Gynecol Obstet; 2016 Jan; 293(1):177-181. PubMed ID: 26209972
[TBL] [Abstract][Full Text] [Related]
46. Loss of heterozygosity alterations associated with progesterone therapy in endometrial hyperplasia and adenocarcinoma.
Yasuda M; Kotajima S; Kajiwara H; Takekoshi S; Osamura RY; Yoshitake T; Muramatsu T; Miyamoto T; Murakami M; Shinozuka T
Int J Gynecol Cancer; 2005; 15(1):155-62. PubMed ID: 15670311
[TBL] [Abstract][Full Text] [Related]
47. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
Hahn HS; Yoon SG; Hong JS; Hong SR; Park SJ; Lim JY; Kwon YS; Lee IH; Lim KT; Lee KH; Shim JU; Mok JE; Kim TJ
Int J Gynecol Cancer; 2009 Aug; 19(6):1068-73. PubMed ID: 19820370
[TBL] [Abstract][Full Text] [Related]
48. Successful use of dydrogesterone as maintenance therapy in recurrent endometrial stromal sarcoma: a case report.
Akashi D; Todo Y; Shimada C; Okamoto K; Minobe S; Kato H
Jpn J Clin Oncol; 2013 Nov; 43(11):1145-9. PubMed ID: 24058200
[TBL] [Abstract][Full Text] [Related]
49. Expression of p53, Ki-67, and CD31 proteins in endometrial polyps of postmenopausal women treated with tamoxifen.
Miranda SP; Traiman P; Cândido EB; Lages EL; Freitas GF; Lamaita RM; Vidigal PV; da Silva Filho AL
Int J Gynecol Cancer; 2010 Dec; 20(9):1525-30. PubMed ID: 21119367
[TBL] [Abstract][Full Text] [Related]
50. Endometrial curettage in abnormal uterine bleeding and efficacy of progestins for control in cases of hyperplasia.
Mesci-Haftaci S; Ankarali H; Yavuzcan A; Caglar M
Asian Pac J Cancer Prev; 2014; 15(8):3737-40. PubMed ID: 24870785
[TBL] [Abstract][Full Text] [Related]
51. 5-aza-2'-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy.
Hu Q; Yu L; Chen R; Wang YL; Ji L; Zhang Y; Xie Y; Liao QP
Int J Gynecol Cancer; 2012 Jul; 22(6):951-9. PubMed ID: 22683940
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer.
Tamauchi S; Kajiyama H; Utsumi F; Suzuki S; Niimi K; Sakata J; Mizuno M; Shibata K; Kikkawa F
J Obstet Gynaecol Res; 2018 Jan; 44(1):151-156. PubMed ID: 29121428
[TBL] [Abstract][Full Text] [Related]
53. The ultrastructural response of human endometrium to medroxyprogesterone acetate.
Roberts DK; Horbelt DV; Powell LC
Am J Obstet Gynecol; 1975 Dec; 123(8):811-8. PubMed ID: 173189
[TBL] [Abstract][Full Text] [Related]
54. Development of a preclinical model for hormonal therapy of human endometrial carcinomas.
Satyaswaroop PG
Ann Med; 1993 Apr; 25(2):105-11. PubMed ID: 8489746
[TBL] [Abstract][Full Text] [Related]
55. The functional morphology of the human endometrium and decidua.
Spornitz UM
Adv Anat Embryol Cell Biol; 1992; 124():1-99. PubMed ID: 1561944
[TBL] [Abstract][Full Text] [Related]
56. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
Zhao S; Chen X; Lu X; Yu Y; Feng Y
Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
[TBL] [Abstract][Full Text] [Related]
57. [Treatment of recurrent uterine endometrial cancer in adjuvant therapy with medroxyprogesterone acetate (MPA) in addition of etoposide].
Ishizaki T; Yamamoto T; Itoh R; Yasuda J; Fujita H; Okada H
Gan To Kagaku Ryoho; 1995 Jan; 22(1):137-40. PubMed ID: 7826070
[TBL] [Abstract][Full Text] [Related]
58. Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate.
Nakayama K; Ishikawa M; Nagai Y; Yaegashi N; Aoki Y; Miyazaki K
Int J Clin Oncol; 2010 Apr; 15(2):179-83. PubMed ID: 20217451
[TBL] [Abstract][Full Text] [Related]
59. [Hormonal therapy and chemotherapy of endometrial cancer].
Krauss T; Huschmand H; Hinney B; Viereck V; Emons G
Zentralbl Gynakol; 2002 Jan; 124(1):45-50. PubMed ID: 11873314
[TBL] [Abstract][Full Text] [Related]
60. Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: single-arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2009).
Kim MK; Seong SJ; Lee TS; Kim JW; Nam BH; Hong SR; Suh KS
Jpn J Clin Oncol; 2012 Dec; 42(12):1215-8. PubMed ID: 23071290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
